UNRESECTABLE PANCREATIC CARCINOMA
Clinical trials for UNRESECTABLE PANCREATIC CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE PANCREATIC CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE PANCREATIC CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in adults with advanced solid tumors that have spread or can't be removed by surgery. The main goal is to find the safest dose and check for side effects. About 66 participants with…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New drug combo shows promise for Hard-to-Treat GI cancers
Disease control OngoingThis study is testing a combination of two drugs, pelareorep and atezolizumab, in people with advanced or metastatic gastrointestinal cancers like anal and pancreatic cancer. The goal is to see if the combination is safe and can shrink tumors or slow disease progression. About 12…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Oncolytics Biotech • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New drug duo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a combination of two drugs, guadecitabine and durvalumab, in people with advanced liver, pancreatic, bile duct, or gallbladder cancer that has spread. The goal is to find the best dose and see if the combination is safe and can shrink tumors. About 55…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New drug combo targets BRCA cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy)—in people with BRCA-mutated breast, pancreas, or ovarian cancers that have spread or cannot be surgically removed. The goal is to see if the combo can shrink tu…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
Could a diabetes drug and supplements boost chemo for pancreatic cancer?
Disease control OngoingThis early-phase study tests whether adding the diabetes drug metformin and a specific dietary supplement mix to standard chemotherapy is safe and feasible for people with pancreatic cancer that cannot be removed by surgery. The supplement includes ingredients like curcumin, vita…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC